Navigation Links
New Drug, Other Trends To Double Smoking Cessation and Addiction Treatments

With the advent of a possible new blockbuster drug and greater reimbursement levels for the treatment of nicotine, alcohol, and drug addictions, global sales of smoking cessation and addiction treatments are expected to rise from revenues of little over $1.1 billion in 2005 to more than $2.3 billion in 2010, according to Smoking Cessation and Addiction Treatments: A World Market Analysis, a new study released today from Kalorama Information.

Nicotine is clearly the most abused drug worldwide, with over 1.4 billion incidences, including 50 million users in the U.S. alone. Smoking cessation has continually become a particular focus of global health agencies, and the increasing high awareness of effective smoking cessation products have helped to drive market growth.

The market now dominated by GlaxoSmithKline with its Zyban smoking cessation treatment, and Schering-Plough / Reckitt Benckiser with their Suboxone/Subetex substance abuse treatment, is primed for a dramatic change as Pfizer moves into smoking cessation.

"We believe Pfizer's Chantix will acquire the largest share of the market, overtaking GlaxoSmithKline in smoking cessation, and leading all addiction treatments based on the superior effectiveness of Pfizer's product in clinical studies," notes Melissa Elder, the report's author. "To a more limited extent, new drugs in alcohol and substance abuse treatments will also change those markets."

Smoking Cessation and Addiction Treatments: A World Market Analysis includes world incidence and data for nicotine addiction, drug addiction, and alcohol abuse; current and forecasted revenues through 2010; current and forecasted market share with consideration of new players in the market; reviews of current products and new products in the pipeline; and key trends driving pharmaceutical treatments for smoking cessation and drug/alcohol addiction.


Page: 1

Related medicine news :

1. FDA Approves New HIV Drug, Viread
2. FDA Approves New Arthritis Drug, Bextra
3. New Drug, Pleconaril speeds recovery from common cold
4. Herceptin Not A ‘Wonder’ Drug, Says The Lanct
5. NGO Files Pre-Grant Opposition Against Anti-HIV Drug, Combivir
6. Life-Saving Cancer Drug, Herceptin Will be Available Free for Breast Cancer Patients in Wales
7. Diabetes Drug, Exenatide, Good For Blood Sugar Levels and Weight Loss
8. FDA Gives Approval for Skin Cancer Drug, Zolinza
9. Was the Warning of a Severe Reaction To a Drug, Overlooked?
10. Anti-Craving Drug, Naltrexone Helps Women Quit Smoking
11. Teen Marijuana Use Does Not Predict Drug, Alcohol Abuse
Post Your Comments:

(Date:12/1/2015)... ... 01, 2015 , ... Nurotron Biotechnology Co., Ltd., maker of cochlear implant systems, ... , The order will be from the China Disabled Persons’ Federation, a central government ... effective solution for children and adults suffering from severe and profound hearing loss ...
(Date:11/30/2015)... ... 2015 , ... Third Molar SEO , one of ... launched a sleek, mobile-ready and user-centric redesigned website. , Vivek Srivastava, founder and ... the benefits that its SEO services provide to dentists and why Third Molar ...
(Date:11/30/2015)... (PRWEB) , ... December 01, 2015 , ... ... Christina Colon as a 2015-2016 inductee into its VIP Woman of ... pharmacy. NAPW is the nation’s leading networking organization exclusively for professional women, boasting ...
(Date:11/30/2015)... ... 01, 2015 , ... Live Very Well is excited to ... on . The multi-carrier insurance exchange platform offers individual vision and ... to compare, quote and match plans to meet their needs. , Beginning ...
(Date:11/30/2015)... ... November 30, 2015 , ... Stress, anxiety, illness, infection or even ... about possible tumors? , Heather Spader, MD, a new pediatric neurosurgeon at Joe DiMaggio ... signs might point to tumors. , “Bad headaches that don’t go away, ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... , Nov. 30, 2015  QT Vascular Ltd., ... and together with its subsidiaries, TriReme Medical LLC and ... company engaged in the design, assembly and distribution of ... vascular disease, is pleased to announce that a three-judge ... Court of Appeals for the Federal Circuit ("Federal Circuit") ...
(Date:11/30/2015)... Nov. 30, 2015  DURECT Corporation (Nasdaq: ... Matt Hogan , Chief Financial Officer, will ... on Tuesday, December 8 at 2:45 pm ... at the Westin Grand Central Hotel in ... for one-on-one meetings at this conference; interested ...
(Date:11/30/2015)... DUBLIN , Nov. 30, 2015 ... addition of the "Orphan Drugs Market 2015-2019" ... ) has announced the addition of the ... their offering. --> Research and Markets ... the "Orphan Drugs Market 2015-2019" report ...
Breaking Medicine Technology: